Morgan Lewis represented Cyclerion Therapeutics in the transaction. Cyclerion Therapeutics Inc. closed a licensing agreement with Akebia Therapeutics Inc. for the development and commercialization of praliciguat,...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here